As for this invention, the chemical compound formula (i), < Conversion 1 > Is not something which it limits, but ankylosing spondylitis and the ateromu artery muscardine, the arthritis (for example, riumachi way arthritis, infection Characteristic arthritis, child arthritis, dry Ichthyosis Characteristic arthritis and reactivity arthritis etc) and the bone-related disease (those which participate in bone formation it is listed), the breast cancer (in anti- estrogen remedy refractory ones and the like), the circulatory organ disease and the cartilage-related disease (for example, disease which it is related to cartilage damage/denaturation, cartilage denaturation, and cartilage formation), the cartilage strange formation symptom, the cartilage sarcoma, the chronic lumbago, the chronic bronchitis, the chronic inflammation Characteristic windpipe disease and the chronic blockade Characteristic lung disease, diabetesThe energy homeostasis disease, the gout and the false gout, the lipid abnormal symptom, metabolic syndrome, the occurring frequently Characteristic marrow swelling, the obesity, the deformans arthropathy, the bone formation incomplete symptom, bone Characteristic bone transfer, the osteomalacia and the osteoporosis symptom, the pejietsuto illness, the gearwheel lap the illness and the riumachi Characteristic occurring frequently Characteristic myalgia, lighter/writer syndrome, the repetition motion overage damage and the high blood glucose symptom, high blood glucose value, and these chemical compounds in order to deal with insulin resistance, it regards the preparation manner of the constituent, the intermediate field and the derivative.本発明は、式(I)の化合物、【化1】限定するものではないが、強直性脊椎炎、アテローム性動脈硬化症、関節炎(例えば、リウマチ様関節炎、感染性関節炎、小児関節炎、乾癬性関節炎、反応性関節炎など)、骨関連疾患(骨形成に関与するものが挙げられる)、乳癌(抗エストロゲン治療に不応性のものなど)、循環器疾患、軟骨関連疾患(例えば、軟骨損傷/変性、軟骨変性、及び軟骨形成に関連する疾患)、軟骨異形成症、軟骨肉腫、慢性腰痛、慢性気管支炎、慢性炎症性気道疾患、慢性閉塞性肺疾患、糖尿病、エネルギー恒常性疾患、痛風、偽痛風、脂質異常症、メタボリック症候群、多発性骨髄腫、肥満症、変形性関節症、骨形成不全症、溶骨性骨転移、骨軟化症、骨粗鬆症、ページェット病、歯周病、リ
